Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with age equal to or over 18 years old,~* Patients with proved hereditary hemochromatosis with homozygosity for the C282Y mutation of the HFE gene,~* Patients with rheumatism related to hemochromatosis, considered by the rheumatologist refractory to usual treatment defined by a persistent painful symptomatology despite a treatment of at least one month with level 2 analgesics (weak opioids) at maximal dose, NSAID, colchicine, steroid injection or a combination of these treatments,~* Patients with pain \> 40/100mm measured by VAS (pain of the last 48 hours),~* Effective contraception to be used during treatment and until 48h after the last administration for women of reproductive age,~* Patients who have given written informed consent.~Exclusion Criteria:~* Other cause of inflammatory rheumatisms such as Rheumatoid Arthritis, Spondyloarthropathies, psoriatic arthritis, or systemic diseases,~* Ongoing treatment with Methotrexate, Hydroxychloroquine, biologic or immunosuppressive drugs~* Malignant pathology, monoclonal gammopathy,~* Intolerance to anakinra,~* Contraindications to the use of anakinra: pregnancy or breastfeeding, hypersensitivity to any of the excipients or to proteins from E. coli, severe renal impairment (creatinine clearance \<30 ml / minute), neutropenia (neutrophil count \<1.5 x 109 / l), ongoing infection~* Patients that cannot follow the protocol,~* Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period

Based on this trial design, predict the completion outcome and termination type (if applicable).